Table 1.
Adverse events in adalimumab psoriasis trials
| Common adverse events in phase III psoriasis trial of adalimumab (Menter et al 2007) | |
|---|---|
| Adverse event | % reported |
| Upper respiratory infection | 7.2% |
| Nasopharyngitis | 5.3% |
| Headache | 4.9% |
| Injection site reactions | 3.1% |
|
Serious adverse events in RA open label adalimumab trial (Burmester et al 2007) | |
| Adverse event | % reported |
| Serious infections | 1.7% |
| Malignanciesa | 0.65% |
| Congestive heart failurea | 0.3% |
| Demyelinating diseasea | 0.06% |
| Systemic lupus erythematosus | 0.03% |
a
Inclusive of adalimumab monotherapy and adalimumab plus disease-modifying antirheumatic drugs.